Cambrian BioPharma raises $123.8 million in Rule 506(c) equity offering
Cambrian BioPharma Inc, a Delaware biotechnology corporation, conducted a Rule 506(c) general solicitation equity offering with a total target of $129,751,064. As of the Form D filing, the company had sold $123,751,064 to 80 investors, representing 95% of the target. The offering permits up to $6,000,000 in remaining securities.
Key facts
- $123,751,064 sold to date
- 80 investors
- $129,751,064 total offering target
- Rule 506(c) general solicitation
- First sale date: June 30, 2026
- Equity securities
Why it matters
The offering demonstrates Cambrian BioPharma's ability to raise substantial capital from accredited investors under Regulation D, providing funding for biotechnology development and operations.
Share
Derived from D filed 2026-07-15. Not investment advice. View the source filing on SEC.gov →